L'analisi dello stato molecolare del gene p53 può contribuire ad innovare le strategie terapeutiche nel carcinoma della mammella?

Translated title of the contribution: Can analysis of the molecular status of the p53 gene contribute to improving the therapeutic strategy for breast carcinoma?

E. Ricevuto, P. Marchetti, K. Cannita, F. De Galitiis, Z. C. Di Rocco, A. Tessitore, F. Martella, R. Bisegna, G. Porzio, A. Bafile, R. Vicentini, V. Resta, S. Mattucci, T. Ventura, S. Martinotti, G. P. de Rubeis, C. Ficorella

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The occurrence of mutations in the p53 tumor suppressor gene is a specific and recurring genetic event in solid tumors. P53 plays a pivotal role in multiple cellular processes such as cell growth control, DNA repair and programmed cell death. Genotoxic damage, also induced by chemotherapy or radiotherapy, induces p53 overexpression in order to control the rate of proliferating damaged cells, thus triggering the mismatch repair or apoptotic pathways. P53 inactivation determines a condition of genetic instability, justifying the subsequent susceptibility to acquire mutations of different other genes. P53 mutations are associated with worse prognosis and with chemo/radioresistance, due to the inability to trigger p53-dependent programmed cell death. Molecular diagnostic strategies show 32% p53 mutations in breast cancer. The analysis of the p53 gene performed by FAMA (Fluorescence Assisted Mismatch Analysis) in high-risk breast cancer patients with > or = 10 involved axillary nodes may help identify a subset of very high risk BC patients (vHR-BC) with poorer prognosis and a subset with better prognosis, potentially responsive to medical treatments. The accurate evaluation of the p53 status can predict prognosis and sensitivity to chemotherapy, thus representing the first step toward better definition of therapeutic strategies according to the molecular characterization of the individual patient.

Original languageItalian
Pages (from-to)197-199
Number of pages3
JournalTumori
Volume89
Issue number4 Suppl
Publication statusPublished - Jul 2003

Fingerprint

p53 Genes
Breast Neoplasms
Mutation
Cell Death
Drug Therapy
DNA Mismatch Repair
Molecular Pathology
Therapeutics
Tumor Suppressor Genes
DNA Repair
Radiotherapy
Fluorescence
Growth
Genes
Neoplasms

ASJC Scopus subject areas

  • Cancer Research

Cite this

Ricevuto, E., Marchetti, P., Cannita, K., De Galitiis, F., Di Rocco, Z. C., Tessitore, A., ... Ficorella, C. (2003). L'analisi dello stato molecolare del gene p53 può contribuire ad innovare le strategie terapeutiche nel carcinoma della mammella? Tumori, 89(4 Suppl), 197-199.

L'analisi dello stato molecolare del gene p53 può contribuire ad innovare le strategie terapeutiche nel carcinoma della mammella? / Ricevuto, E.; Marchetti, P.; Cannita, K.; De Galitiis, F.; Di Rocco, Z. C.; Tessitore, A.; Martella, F.; Bisegna, R.; Porzio, G.; Bafile, A.; Vicentini, R.; Resta, V.; Mattucci, S.; Ventura, T.; Martinotti, S.; de Rubeis, G. P.; Ficorella, C.

In: Tumori, Vol. 89, No. 4 Suppl, 07.2003, p. 197-199.

Research output: Contribution to journalArticle

Ricevuto, E, Marchetti, P, Cannita, K, De Galitiis, F, Di Rocco, ZC, Tessitore, A, Martella, F, Bisegna, R, Porzio, G, Bafile, A, Vicentini, R, Resta, V, Mattucci, S, Ventura, T, Martinotti, S, de Rubeis, GP & Ficorella, C 2003, 'L'analisi dello stato molecolare del gene p53 può contribuire ad innovare le strategie terapeutiche nel carcinoma della mammella?', Tumori, vol. 89, no. 4 Suppl, pp. 197-199.
Ricevuto, E. ; Marchetti, P. ; Cannita, K. ; De Galitiis, F. ; Di Rocco, Z. C. ; Tessitore, A. ; Martella, F. ; Bisegna, R. ; Porzio, G. ; Bafile, A. ; Vicentini, R. ; Resta, V. ; Mattucci, S. ; Ventura, T. ; Martinotti, S. ; de Rubeis, G. P. ; Ficorella, C. / L'analisi dello stato molecolare del gene p53 può contribuire ad innovare le strategie terapeutiche nel carcinoma della mammella?. In: Tumori. 2003 ; Vol. 89, No. 4 Suppl. pp. 197-199.
@article{69c8ac63218846eea9b00cc13396179b,
title = "L'analisi dello stato molecolare del gene p53 pu{\`o} contribuire ad innovare le strategie terapeutiche nel carcinoma della mammella?",
abstract = "The occurrence of mutations in the p53 tumor suppressor gene is a specific and recurring genetic event in solid tumors. P53 plays a pivotal role in multiple cellular processes such as cell growth control, DNA repair and programmed cell death. Genotoxic damage, also induced by chemotherapy or radiotherapy, induces p53 overexpression in order to control the rate of proliferating damaged cells, thus triggering the mismatch repair or apoptotic pathways. P53 inactivation determines a condition of genetic instability, justifying the subsequent susceptibility to acquire mutations of different other genes. P53 mutations are associated with worse prognosis and with chemo/radioresistance, due to the inability to trigger p53-dependent programmed cell death. Molecular diagnostic strategies show 32{\%} p53 mutations in breast cancer. The analysis of the p53 gene performed by FAMA (Fluorescence Assisted Mismatch Analysis) in high-risk breast cancer patients with > or = 10 involved axillary nodes may help identify a subset of very high risk BC patients (vHR-BC) with poorer prognosis and a subset with better prognosis, potentially responsive to medical treatments. The accurate evaluation of the p53 status can predict prognosis and sensitivity to chemotherapy, thus representing the first step toward better definition of therapeutic strategies according to the molecular characterization of the individual patient.",
author = "E. Ricevuto and P. Marchetti and K. Cannita and {De Galitiis}, F. and {Di Rocco}, {Z. C.} and A. Tessitore and F. Martella and R. Bisegna and G. Porzio and A. Bafile and R. Vicentini and V. Resta and S. Mattucci and T. Ventura and S. Martinotti and {de Rubeis}, {G. P.} and C. Ficorella",
year = "2003",
month = "7",
language = "Italian",
volume = "89",
pages = "197--199",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4 Suppl",

}

TY - JOUR

T1 - L'analisi dello stato molecolare del gene p53 può contribuire ad innovare le strategie terapeutiche nel carcinoma della mammella?

AU - Ricevuto, E.

AU - Marchetti, P.

AU - Cannita, K.

AU - De Galitiis, F.

AU - Di Rocco, Z. C.

AU - Tessitore, A.

AU - Martella, F.

AU - Bisegna, R.

AU - Porzio, G.

AU - Bafile, A.

AU - Vicentini, R.

AU - Resta, V.

AU - Mattucci, S.

AU - Ventura, T.

AU - Martinotti, S.

AU - de Rubeis, G. P.

AU - Ficorella, C.

PY - 2003/7

Y1 - 2003/7

N2 - The occurrence of mutations in the p53 tumor suppressor gene is a specific and recurring genetic event in solid tumors. P53 plays a pivotal role in multiple cellular processes such as cell growth control, DNA repair and programmed cell death. Genotoxic damage, also induced by chemotherapy or radiotherapy, induces p53 overexpression in order to control the rate of proliferating damaged cells, thus triggering the mismatch repair or apoptotic pathways. P53 inactivation determines a condition of genetic instability, justifying the subsequent susceptibility to acquire mutations of different other genes. P53 mutations are associated with worse prognosis and with chemo/radioresistance, due to the inability to trigger p53-dependent programmed cell death. Molecular diagnostic strategies show 32% p53 mutations in breast cancer. The analysis of the p53 gene performed by FAMA (Fluorescence Assisted Mismatch Analysis) in high-risk breast cancer patients with > or = 10 involved axillary nodes may help identify a subset of very high risk BC patients (vHR-BC) with poorer prognosis and a subset with better prognosis, potentially responsive to medical treatments. The accurate evaluation of the p53 status can predict prognosis and sensitivity to chemotherapy, thus representing the first step toward better definition of therapeutic strategies according to the molecular characterization of the individual patient.

AB - The occurrence of mutations in the p53 tumor suppressor gene is a specific and recurring genetic event in solid tumors. P53 plays a pivotal role in multiple cellular processes such as cell growth control, DNA repair and programmed cell death. Genotoxic damage, also induced by chemotherapy or radiotherapy, induces p53 overexpression in order to control the rate of proliferating damaged cells, thus triggering the mismatch repair or apoptotic pathways. P53 inactivation determines a condition of genetic instability, justifying the subsequent susceptibility to acquire mutations of different other genes. P53 mutations are associated with worse prognosis and with chemo/radioresistance, due to the inability to trigger p53-dependent programmed cell death. Molecular diagnostic strategies show 32% p53 mutations in breast cancer. The analysis of the p53 gene performed by FAMA (Fluorescence Assisted Mismatch Analysis) in high-risk breast cancer patients with > or = 10 involved axillary nodes may help identify a subset of very high risk BC patients (vHR-BC) with poorer prognosis and a subset with better prognosis, potentially responsive to medical treatments. The accurate evaluation of the p53 status can predict prognosis and sensitivity to chemotherapy, thus representing the first step toward better definition of therapeutic strategies according to the molecular characterization of the individual patient.

UR - http://www.scopus.com/inward/record.url?scp=0042380212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042380212&partnerID=8YFLogxK

M3 - Articolo

VL - 89

SP - 197

EP - 199

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4 Suppl

ER -